As tomorrow’s innovations are developed by today’s entrepreneurs, we invest in transformational scientific opportunities aligned with our core R&D interests to gain access to next-generation science and build relationships with proven and emerging scientific leaders.
Investing since 2009, we focus exclusively on novel, transformational therapeutics at discovery and pre-clinical stages. Aligning with AbbVie’s strategic focus, our investments address critical needs in oncology, immunology, neuroscience, eye care, and aesthetics. We offer our partners access to AbbVie’s vast internal network of experts in all phases of drug development, from drug discovery through successful commercialization.
Our current portfolio is comprised of over 20 companies based in the US and Europe. Targeting six to eight new investments annually, predominantly at the Seed or Series A stage, we have the capability and flexibility to create new companies, and lead or co-lead a syndicate. Our team of dedicated investing professionals is based in three locations: Cambridge (MA), San Francisco (CA), and Oxford (UK).
Head of AbbVie Ventures - Cambridge, MA
Christian is a trained geneticist, neurobiologist, and biochemist with global big pharma and large biotech experience, and an ever-curious biotech startup mindset. He brings broad strategic and deep operational expertise in company creation, venture investing, external innovation, business development, and R&D to AbbVie Ventures. Passionate about drug discovery and value creation through scientific entrepreneurship to serve patients across the biopharmaceutical value chain, Christian has built and led successful partnering teams across biotech hubs in the US, Europe, and Asia-Pacific.
Executive Director - Irvine, CA
Doug is an entrepreneurial life scientist-PhD immunologist with more than twenty years of professional experience spanning both major pharmaceutical and academic environments. His collective expertise includes leading search and evaluation efforts for business development and external strategic partnering opportunities, therapeutic area corporate strategy, drug repositioning-asset/indication pairing, and both preclinical and clinical development. With an emphasis on innovation, creative and strategic partnerships, and cross-functional team leadership, Doug brings broad experience across the disciplines of immunology and inflammation specializing in ophthalmology, dermatology, gene and cell therapies, and aesthetics.
Director - San Francisco, CA
Shawna brings a familiarity of the biotech ecosystem from both sides of the table. She is an experienced life science venture capital investor with prior investments in private and public biotech companies, participating in Series A financings through IPO and beyond. She also has Corporate Strategy and Business Development experience and was herself Co-Founder and Scientific Advisor of a bay area startup developing therapeutics for neurological and ocular indications. A biochemist/biophysicist by training, her prior research experience spans the areas of cellular physiology, molecular engineering, synthetic biology and gene therapy.
Director - Oxford, UK
Donmienne is a strategic thinker and a passionate drug hunter with decades of experience in pre-clinical research where she delivered valuable clinical assets to treat the unmet needs of patients. She broke boundaries to stride the interface of small molecule chemistry and biologics research with a collaborative mindset to connect scientists in her expanding network around the world.
Managing Director – Cambridge, MA
Claire is a trained molecular and cellular biologist with extensive experience leading preclinical and clinical drug development programs. Claire marries the breadth of her broad technological reach, with prime experience in all stages of investments (Seed, A, B, C, IPO, PIPE, SPAC) which she acquired in established corporate venture funds. With this totality, she has proven to be a catalyst for organizations developing transformative technologies, where she is known to build bespoke deal financing structures and business models to generate progress in the community.
Claire has a PhD from the Institute of Genetics, Molecular and Cellular Biology of Strasbourg-Illkirch France, and a Master of Business Administration from the Massachusetts Institute of Technology, Sloan School (Cambridge MA). She has 14 years of experience in drug development acquired at Forenap Pharma, Wyeth Pharmaceuticals, and Pfizer Inc. She was an investor at Samsung Venture America (SVA), Johnson & Johnson Development Corporation (JJDC), and most recently was an Entrepreneur in Residence at the National Institutes of Health (Bethesda, MD).
Associate Director - San Francisco, CA
Danjuma is a trained computational biologist with a background in human genomics and statistical genetics that started in the AbbVie Genetics Research Center before transitioning to AbbVie Ventures in the Corporate Strategy Organization. He joined the team after simultaneously completing the Strategy Leadership Development program and an MBA from the Kellogg School of Business at Northwestern. Danjuma is passionate about early cutting-edge science, novel drug development technologies, and external biopharmaceutical innovation to ultimately improve patient lives.
Director - Ludwigshafen, Germany
Joachim spent more than 20 years in the pharmaceutical and biotech industry in BD and research roles. He is enthusiastic about cutting-edge technologies and projects that ultimately can be developed into new medicines. Joachim holds a diploma in chemistry and received his PhD in protein crystallography at the University of Freiburg.
Director - Cambridge, MA
Christina Vorvis, PhD is Director, East Coast Ventures at AbbVie, where she leads investments in early-stage companies developing transformative therapies and technologies for cancer, immunology, neuroscience, eye care, and aesthetics based in Cambridge, Massachusetts. Christina has over 10 years of experience in the Life Sciences, including benchside research, digital health startups, investment banking, and deal origination and deal execution at global institutions like Amgen, OrbiMed, and Back Bay Life Science Advisors. She earned her PhD in Cancer Biology from the University of California, Los Angeles where she studied the molecular mechanisms of tumor growth and progression in pancreatic cancer. Prior to joining AbbVie, Christina advised biotech and pharmaceutical companies on mergers and acquisitions, financings, and other strategic transactions. In her current role at AbbVie, Christina is passionate about using her expertise to help innovative companies develop and commercialize new therapies and technologies that improve the lives of patients around the world.
Associate Director – Cambridge, MA
Shann is a globally minded strategic thinker whose training in bioengineering and immunology took him across three continents. He joined AbbVie as part of the Strategic Leadership Program, where he gained experience in business development, decision sciences, and pipeline analytics prior to joining AbbVie Ventures. Shann is passionate about enabling complete cures and improving the lives of patients through innovative science.
To read more about our 2023 accomplishments, download our Year-In-Review brochure.
Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.
Copyright © 2025 AbbVie Inc. North Chicago, Illinois, U.S.A.